Renal cell carcinoma (RCC), with high morbidity and mortality, is one of the top ten serious cancers. Due to limited therapies and little knowledge about the mechanism underlying RCC, overall survival of RCC patients is poor. UBE2C is a member of ubiquitin modification system and promotes carcinogenesis in cancer, but its role in RCC is unknown. Based on the TCGA (The Cancer Genome Atlas) data, UBE2C was over-expressed in a total of 525 RCC tissues and displayed higher expression in advanced tissues (stage IV vs stage I, p<0.05). RT-qPCR and IHC analysis confirmed over-expression of UBE2C in 90 of clinical RCC tissues. Further, UBE2C was associated with clinical factors including TNM stage, gender, and pathological stage. And higher UBE2C expression predicted shorter overall survival and progression-free survival. Both univariate and multivariate COX analysis suggested UBE2C as a critical gene in RCC. Then GO and KEGG analysis showed that cell cycle and DNA replication pathways were two top signaling pathways affected by UBE2C. In vitro assay showed that knockdown of UBE2C in 786-O cells inhibited proliferation and migration significantly. Therefore, this study proves that UBE2C is an important gene in RCC and is essential to proliferation and migration of RCC.

肾细胞癌（RCC）具有较高的发病率和死亡率，是十大严重癌症之一。由于有限的疗法和对 RCC 潜在机制的了解很少，RCC 患者的总生存率很差。UBE2C 是泛素修饰系统的成员，在癌症中促进致癌作用，但其在 RCC 中的作用尚不清楚。根据 TCGA（癌症基因组图谱）数据，UBE2C 在总共 525 个 RCC 组织中过度表达，并在晚期组织（IV 期与I期，p<0.05）。RT-qPCR 和 IHC 分析证实了 UBE2C 在 90 个临床 RCC 组织中的过度表达。此外，UBE2C 与临床因素相关，包括 TNM 分期、性别和病理分期。较高的 UBE2C 表达预测较短的总生存期和无进展生存期。单变量和多变量 COX 分析均表明UBE2C是 RCC 中的关键基因。然后GO和KEGG分析表明，细胞周期和DNA复制通路是受UBE2C影响的两条主要信号通路。体外试验表明，敲低786-O 细胞中的UBE2C 可显着抑制增殖和迁移。因此，本研究证明UBE2C 是 RCC 中的一个重要基因，对 RCC 的增殖和迁移至关重要。